Rohto Pharmaceutical Co.Ltd. (RPHCF) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Rohto Pharmaceutical Co.L...

    PNK: RPHCF · Real-Time Price · USD
    20.09
    -6.54 (-24.56%)
    At close: Jan 24, 2025, 9:00 PM

    Rohto Pharmaceutical Income Statement

    Financials in JPY. Fiscal year is April - March.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Mar 31, 2024 Mar 31, 2023 Mar 31, 2022 Mar 31, 2021
    Revenue
    		 270.84B 1.8B 1.64B 1.64B
    Cost of Revenue
    		 113.55B 779.29M 702.78M 688.64M
    Gross Profit
    		 157.29B 1.02B 937.32M 949.85M
    Operating Income
    		 40.05B 252.44M 228.85M 197.89M
    Interest Income
    		 1.52B 7.24M 3.02M 3.09M
    Pretax Income
    		 41.52B 258.1M 228.98M 208.2M
    Net Income
    		 30.94B 198.54M 173.57M 151.52M
    Selling & General & Admin
    		 54.22B 681.04M 636.33M 680.06M
    Research & Development
    		 13.39B 83.66M 72.14M 71.89M
    Other Expenses
    		 49.63B -63M 246M 260M
    Operating Expenses
    		 117.24B 764.7M 708.46M 751.95M
    Interest Expense
    		 196M 1.86M 2.04M 1.31M
    Selling & Marketing Expenses
    		 54.22B 46.47B 38.11B 40.52B
    Cost & Expenses
    		 230.79B 1.54B 1.41B 1.44B
    Income Tax Expense
    		 10.12B 59.16M 54.93M 56.43M
    Shares Outstanding (Basic)
    		 228.14M 228.14M 228.14M 228.14M
    Shares Outstanding (Diluted)
    		 228.8M 228.8M 228.8M 228.8M
    EPS (Basic)
    		 135.60 0.87 0.76 0.66
    EPS (Diluted)
    		 135.21 0.87 0.76 0.66
    EBITDA
    		 50.4B 42.34B 35.81B 29.9B
    EBIT
    		 41.71B 34.54B 28.12B 23.15B
    Depreciation & Amortization
    		 8.69B 7.8B 7.69B 6.75B

    Add to Watchlist